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Abstract
Background: Cell proliferation is associated with the pathogenesis of cancer because it provides opportunities for accumulating genetic 
mutations. However, biomarkers of cell proliferation in response to environmental stimuli have not been adequately explored for breast 
cancer risk.
Methods: In a case-control study of 200 breast cancer patients and 360 healthy controls, we investigated the association between 
phytohemagglutinin (PHA)-induced mitotic index in blood lymphocyte and breast cancer risk.
Results: Having high mitotic index (.3.19%) was associated with an increased risk of breast cancer, with adjusted odds ratios (95% 
confidence interval) of 1.54 (1.03–2.30) and 2.03 (1.18–3.57) for all women and post-menopausal women, respectively. Mitotic index 
was correlated with some reproductive factors and body mass index in controls.
Conclusions: Our data suggest increased PHA-induced mitotic index in blood lymphocytes is associated with an increased breast 
cancer risk and that this association may be modulated by reproductive and other hormones.
Keywords: breast cancer, mitogens, mitotic index, biomarker, cell proliferation, lymphocytesKosti et al
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Introduction
Breast cancer is the most common malignancy1 and 
the  second  leading  cause  of  cancer-related  death 
in  women.2,3  In  the  United  States,  over  the  last 
two decades the annual incidence of breast cancer has 
been increasing4 while survival rates of patients with 
early  breast  cancer  have  improved  steadily  due  to 
early diagnosis and more effective therapy regimens.5 
Additional gains would come by the development of 
methods  that  can  predict  which  individual  woman 
is most likely to develop the disease in the general 
population, allowing focused prevention on women 
at the greatest risk. Of the nearly 241,000 women 
diagnosed each year, about 90% are sporadic cases 
among women without a significant family history 
of breast cancer and no other strong identifiable risk 
factors other than age and reproductive or hormonal 
risk factors.6
Cell proliferation has long been associated with the 
pathogenesis of cancer because it provides opportuni-
ties for the accumulation of genetic mutations. Cells 
that do not replicate in adults, such as cardiomyocytes, 
never develop tumors.7 In contrast, malignant tumors 
occur frequently in tissues that are characterized by 
active renewal, such as the epithelium of the mammary 
gland that undergoes dramatic morphogenetic changes, 
especially during the reproductive years of a woman.8 
Moreover, hyperproliferative lesions of the breast such 
as hyperplasia of the ductal epithelium is associated 
with  a  1.5–2  fold  increased  risk  of  breast  cancer.9 
In  the  breast,  higher  cellular  proliferative  activity 
within the mammary gland confers a higher suscep-
tibility for transformation by chemical carcinogens.10 
From studying breast biopsy tissues, estrogens appear 
to trigger breast cell proliferation and estrogens with 
progesterone together induce more mitoses than estro-
gens alone.11 The normal physiology of the female 
breast is dependent on the proliferative effects of the 
ovarian hormones; estrogens are primarily responsi-
ble for elongation and branching of the breast ducts, 
whereas  progesterone  is  necessary  for  the  lobular 
development and maturation.12
Proliferation  markers,  such  as  Ki-67,  mitotic 
index of tumor cells and cell nuclear antigen (PCNA) 
expression in breast tumor tissues have been extensively 
studied among breast cancer survivors and published 
data  were  recently  reviewed  in  a  meta-analysis.13 
These markers of cancer tissue proliferation predicted 
clinical  outcomes  such  as  response  to  medical 
therapy,14 risk of relapse,15 incidence of lymph node 
metastasis16 and overall survival of the breast cancer 
patient.17 However, these cancer tissue markers are 
not applicable to assessing cancer risk in the general 
healthy population. Given the crucial role of cell pro-
liferation in breast carcinogenesis, biomarkers of cell 
proliferation are potentially valuable tools for breast 
cancer risk assessment.
Circulating  lymphocytes  are  commonly  used 
surrogate cells to measure the cellular function/events 
of other healthy somatic cells. Blood lymphocytes are 
typically resting in G0 of the cell cycle and can be stim-
ulated by mitogens to divide in vitro. Among the mito-
gens, phytohemagglutinin (PHA), an extract of red 
kidney beans, stimulates T-cell (thymus dependent) 
fraction of lymphocytes while it has little or no affect 
on the B-cell (bone-marrow-dependent) lymphocyte 
fraction.18 Lymphocyte growth rate in response to PHA 
stimulation varies among healthy individuals.19 In the 
context of cancer, there are few studies that demon-
strated a reduced mitogenic stimulation of peripheral 
blood lymphocytes in cancer cases compared to cancer 
free controls.20–23 The observed lower mitotic index in 
blood lymphocytes in response to PHA stimulation in 
cancer patients has been interpreted as the result of 
compromised immunocompetence in cancer patients. 
However, the direct evidence to support this interpreta-
tion is weak and PHA-induced mitotic index in blood 
lymphocytes  is  likely  a  complex  phenotype  partly 
representing immune function and cell proliferation 
potentials.  In  breast  cancer,  one  previous  study 
reported that PHA-induced lymphocyte proliferation 
was correlated with breast cancer stage and recurrence 
and that the rate of PHA-induced lymphocyte prolifer-
ation was lower in cases than in healthy controls. This 
study was small (90 cases and 60 controls) and other 
host  or  environmental  factors  were  not  considered 
in the analysis.20 We conducted a case-control study 
of 200 cases and 360 controls to further understand 
the relationship between PHA-induced mitotic index 
in blood lymphocytes and breast cancer risk. To shed 
some light on potential etiology, we also examined 
the association between PHA-induced mitotic index 
in blood lymphocytes and other known breast cancer 
risk factors.Blood lymphocyte proliferation index and breast cancer risk
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Materials and Methods
Study population
The  study  population  was  described  previously.24 
Breast cancer cases (n = 200) were recruited at the 
Georgetown  University  Hospital  clinics  (Lombardi 
Comprehensive  Cancer  Center’s  [LCCC]  Division 
of Medical Oncology, Department of Surgery and the 
Betty Lou Ourisman Breast Health Clinic). The inclu-
sion criteria for cases included a diagnosis of breast 
cancer  within  the  prior  6  months,  in  women  who 
have  not  yet  received  chemotherapy  and/or  radio-
therapy and were able to provide informed consent 
in English. Exclusion criteria included having a prior 
history of cancer, prior chemotherapy and/or radia-
tion therapy, or an active infection or immunologi-
cal disorder that required treatment with antibiotics 
or immunosuppressive medication within one month 
prior to enrollment. From 2006 through 2008, a total 
of 254 newly diagnosed breast cancer patients were 
identified as eligible and 214 (70%) participated in 
our  study.  Common  reasons  for  non-participation 
were: too busy or not interested (21%), overwhelmed 
by cancer diagnosis (5%), and not responsive to phone 
call or e-mail contact (4%). Four cases (2%) did not 
provide a blood sample, 6 blood cultures failed (3%), 
and  blood  culture  was  not  performed  on  4  blood 
samples due to holiday schedule when the laboratory 
was closed (2%). Therefore, the final number of cases 
with mitotic index data was 200.
Between 2006 and 2008, a total of 380 women 
who were recruited by random selection from healthy 
women  who  visited  the  mammography  screening 
clinic at Georgetown University Hospital and each 
donated a blood sample for the lymphocyte culture. 
The exclusion criteria for healthy women were the 
same as for cases. Additionally, women who had a 
breast biopsy within the past 6 months or were   currently 
pregnant or breast feeding were not eligible. The over-
all   participation rate among the eligible women was 
60%. The major reasons for non-  participation were: 
being too busy (19%) or not interested (20%). Blood 
cultures failed in 10 samples (3%), and 10 samples 
(3%)  yielded  poor  quality  slides  for  mitotic  index 
ascertainment, thus the final number of subjects with 
mitotic index data was 360.
After providing informed consent, subjects com-
pleted  a  structured,  in-person  interview  assessing 
prior medical history, tobacco smoke exposures, cur-
rent medications, family medical history, reproductive 
history,  and  socioeconomic  characteristics. Trained 
phlebotomists obtained venous blood using heparin-
ized tubes. The study was approved by the MedStar 
Research Institute-Georgetown University Oncology 
Institutional Review Board.
Blood lymphocyte culture and mitotic 
index ascertainment
Blood  cultures  were  established  within  48  hours 
of  blood  collection  as  described  previously.23 
Briefly,  1  ml  of  fresh  blood  was  added  to  9  ml 
of  RPMI-1640  medium  supplemented  with  15% 
bovine serum, 1.5% phytohemagglutinin (Invitrogen, 
Rockville, MD), 2 mM L-glutamine and 100 U/ml 
each  of  penicillin  and  streptomycin.  To  arrest  the 
cells  at  metaphase,  0.2  µg/ml  colcemid  was  added 
to the culture 1 hour before   harvest. The cells were 
treated in hypotonic solution (0.06M KCL) and fixed 
in  fixative  (methanol:acetic  acid  =  3:1).  The  cells 
were  then  dropped  onto  clean  microscopic  slides, 
air dried, and stained with 4% Gurr’s Giemsa solu-
tion (BDH Laboratory Supplies, Poole, Dorset, UK). 
One thousand cells were examined to visually score 
the percentage of mitotic cells. The slides were coded 
and scored without the knowledge of case-control sta-
tus. In order to assess the reproducibility of the mitotic 
index measurements, blood samples from ∼10% n = 50 
randomly selected subjects were assayed in duplicates. 
The results indicated that mitotic index score in assay 
1 was very similar to that in assay 2 and significantly 
correlated [Pearson correlation coefficiency (r) = 0.80, 
P = 0.01] and the average coefficient of variation for 
the 50 pairs of duplicates was 15%. The overall blood 
culture success rate was 97%.
statistical Analysis
Descriptive analyses were conducted to characterize 
the population using the Student t test for continuous 
variables and chi-square test for categorical variables. 
We used general Linear Models (GLM) to examine the 
association of selected host characteristics and mitotic 
index in the control group, adjusting for age and race 
where appropriate. We categorized the mitotic index 
using informative cutoff points based on the distribu-
tions among the controls and the P-for-trend across Kosti et al
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categories was examined. Smoking status was stratified 
into two categories: never smokers—individuals who 
had never smoked more than 100 cigarettes in their 
life and ever (former/current) smokers—individuals 
who had smoked more than 100 cigarettes in their life. 
Family history of female cancers was defined as hav-
ing breast or ovarian cancer in first or second degree 
biological relatives. Physical activity was defined as 
any physical activity on a regular basis (at least once a 
week on average) for at least 20 minutes at a time that 
was reported to either have made the subjects sweat 
or increased their heart rate. Pearson Correlation was 
used  to  estimate  the  correlations  between  mitotic 
index and the variable of interest. Multivariate logistic 
regression was used to estimate the risk association 
between mitotic index and breast cancer, adjusting for 
age, race, state as well as other known breast cancer 
risk factors and other potential confounders. An indi-
vidual was considered to have high mitotic index if 
the mitotic index score was equal to or greater than the 
50th percentile value in controls (3.19%). To assess 
for a dose-response trend between breast cancer risk 
and mitotic index, women were categorized to three 
groups: lowest quartile, 2 middle quartiles combined 
and highest quartile based on control distributions. All 
P-values were two-sided and considered significant if 
P , 0.05. Analyses were performed using SAS soft-
ware, version 9 (SAS Institute Inc., Cary, NC).
Results
Study population
The demographic characteristics of case-control sub-
jects (200 cases and 360 controls) are presented in 
Table 1. The mean age was 52.7 for cases and 54.2 for 
controls and the population was predominantly white 
(73% of cases versus 62% of controls). There were no 
significant case-control differences in the distribution 
of tobacco smoking status, menopausal status, fam-
ily history of female cancers, hormonal replacement 
therapy (HRT) use and mean body mass index (BMI). 
Eighty  one  percent  of  cases  and  80%  of  controls 
reported to have been pregnant at some point in their 
lifetime and the average number of full term pregnan-
cies was significantly higher in controls than in cases 
(Table 1). Sixty-six percent of cases and 69% of con-
trols ever breastfed and the mean lifetime duration of 
breastfeeding was 57 weeks for cases and 70 weeks 
for controls (P = 0.13, Table 1). Seventy-nine percent 
of controls and 65% of cases had regular physical 
activities in their teens. Forty percent of cases and 
43% of controls had completed college or higher edu-
cation, and 56% of cases and 52% of controls had 
median family income $$100k, reflecting the high 
socioeconomic characteristics of patients seen at the 
Georgetown University Medical Center.
The mean percent of mitotic cells in blood lym-
phocytes was significantly higher in cases (3.59%) 
than in controls (3.26%, P , 0.01, Table 2). When 
the  case-control  comparison  was  stratified  by  age, 
race, menopausal status, BMI, tobacco smoking and 
physical activity during the teenage years, cases con-
sistently  showed  a  higher  mitotic  index  across  all 
subgroups of women than controls (Table 2).
Mitotic index in blood lymphocytes  
and breast cancer risk
We examined the association between mitotic index and 
breast cancer risk using multivariate logistic regression 
(Table 3). Using the median (3.19%) in controls as a 
cut point, subjects were dichotomized into high (equal 
or above median) or low (below median) mitotic index 
groups. Women who had high mitotic index had sig-
nificantly increased breast cancer risk compared with 
women with low mitotic index (adjusted odds ratio 
[OR] = 1.54, 95% Confidence Interval [CI] = 1.03–2.30) 
in the overall study population (Table 3). ORs were 
adjusted for age, race, menopausal status, number of 
full-term pregnancies and lifetime duration of breast-
feeding.  When  stratified  by  menopausal  status,  the 
ORs were 1.14 (95% CI = 0.62–2.09) and 2.06 (95% 
CI = 1.18–3.57) for pre- and post-menopausal women, 
respectively. We also found that the significant asso-
ciations between mitotic index and breast cancer risk 
were  restricted  to  women  who  were  overweight  or 
obese (BMI . 25), (OR = 2.02, 95% CI = 1.19–3.43, 
Table 3). To assess for the presence of a dose-response 
trend between breast cancer risk and mitotic index, 
women were categorized into three groups: low mitotic 
index  (lowest  quartile),  intermediate  mitotic  index 
(2 middle quartile categories) and high mitotic index 
(highest quartile). Women with low mitotic index (the 
lowest quartile) were used as the reference. A significant 
dose-  response relationship was observed (Ptrend , 0.01) 
in all women, and the lowest-versus-highest quartile Blood lymphocyte proliferation index and breast cancer risk
Breast Cancer: Basic and Clinical Research 2010:4  77
OR  was  2.00  (95%  CI  =  1.16–3.47). A  significant 
dose-response relationship was also observed among 
whites,  post-menopausal  women  and  women  who 
were  overweight  or  obese  (Table  3).  No  significant 
dose  response  relationship  was  observed  for  black 
women, premenopausal women, and women who had 
BMI # 25. Further adjustment of the models for BMI 
resulted in comparable results.
Correlation between mitotic index  
and host factors
We evaluated the relationship between mitotic index 
and selected host factors among 360 healthy woman 
controls  (Table  4).  Two  hundred  and  twenty  four 
women were white (62%), 126 were African American 
(35%) and 10 were of ‘other’ race/ethnicity (3%). The 
overall mean mitotic index among all healthy women 
subjects was 3.25%. White women had a significantly 
higher mitotic index (3.35%) compared with African 
American women (3.06%, P , 0.01). We observed a 
trend of decreasing mitotic index with increasing age 
(Table 4). However, there was no noticeable difference 
in  mitotic  index  between  pre-  and  post-menopausal 
women  (Table  2).  Using  Pearson  correlation,  we 
observed a modest inverse association between mitotic 
index  and  BMI  (r  =  −0.19,  P  =  0.0003,  Table  4), 
Table 1. Characteristics of study population by case-control status.
characteristic cases (n = 200) controls (n = 360) P-value*
Age (years), mean (SD) 52.7 (10.9) 54.2 (10.2) 0.11
Race, n (%)
White 147 (73) 224 (62)
Black 42 (21) 126 (35)
Other 11 (6) 10 (3) ,0.01
BMi, mean (SD) 27.1 (6.4) 27.7 (7.2) 0.26
Active smoking, n (%)
ever 71 (36) 148 (41) 0.2
Age at menarche (years), mean (SD) 12.6 (1.5) 12.5 (1.5) 0.58
ever pregnant, n (%)
Yes 161 (81) 288 (80) 0.67
FTP (n), mean (SD) 1.61 (1.2) 2.00 (1.2) ,0.01
Age at 1st FTP (years), mean (SD) 27.3 (6.3) 27.4 (6.6) 0.97
Age at last FTP (years), mean (SD) 31.7 (6.1) 32.0 (5.8) 0.63
Years since last FTP (years), mean (SD) 22.7 (13.3) 23.1 (12.1) 0.75
ever breastfed (%)
Yes 82 (66) 178 (69) 0.43
Weeks breastfed (n), mean (SD) 56.6 (66.7) 70.0 (70.1) 0.13
Menopausal status, n (%)
Post- 108 (56) 218 (61) 0.23
Use of HRT (%)
ever 53 (51) 120 (55) 0.54
physical activity at age 13–19, n (%)
Yes 130 (65) 277 (79) ,0.01
Family history of female cancers, n (%)
0 relatives affected 180 (90) 329 (93.7)
1 relative affected 9 (4.5) 21 (6)
2 relatives affected 1 (0.5) 1 (0.3) 0.76
educational level (%)
equal/above college 80 (40) 153 (43) 0.63
Household income (%)
equal/above $100K 78 (56) 134 (52) 0.38
notes: *P-values were computed using t-tests for continuous characteristics and chi-square tests for categorical characteristics. Missing values were 
excluded from the P-value computation. Physical activity was defined as any weekly physical activity, longer than 20 minutes at a time that would make the 
subject sweat or increase their heart rate. Family history of female cancers was defined as any breast or ovarian cases among 1st and 2nd degree blood 
relatives.
Abbreviations: BMi, body mass index; FTP, full term pregnancy, analyses among parous women only; hRT, hormonal replacement therapy, analysis 
among post-menopausal women, weeks breastfeeding computed only among women that breastfed.Kosti et al
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and  this  correlation  was  only  significant  among 
postmenopausal women (r = −0.24, P = 0.0004) and 
white women (r = −0.26, P , 0.0001, Table 4). We 
also found that mitotic index was modestly correlated 
with household income (r = 0.13, P = 0.04) and educa-
tional level (r = 0.17, P , 0.01). There were no asso-
ciations between mitotic index and family history of 
female  cancers,  smoking  status  or  physical  activity 
during teenage years.
Correlation between mitotic index 
and reproductive factors
We examined the correlations between mitotic index 
and  reproductive  factors  known  to  contribute  to 
breast cancer risk in 360 healthy women controls. 
Because mitotic index differed significantly by race 
and reproductive characteristics also differ between 
white women and African American women, this part 
of the analysis was stratified by race and adjusted for 
age. Among white women, mitotic index was signifi-
cantly correlated with age at menarche (P , 0.01) and 
number of full-term pregnancies (P , 0.01, Table 4). 
Among African American women, mitotic index was 
significantly correlated with age of last full-term preg-
nancy (P = 0.03), and borderline significantly correlated 
with age of first full-term pregnancy (P = 0.08). Con-
sistent  with  previous  reports,22–25  the  distributions  of 
reproductive  characteristics  differed  between  Whites 
and African Americans  in  our  study  population.  For 
example, we observed that a higher percentage of Afri-
can American women had an early age of menarche 
(,11 years of age) compared to white women (31% 
versus 20%). Twenty-eight percent of African American 
women had their first child at age #20 years while only 
2% of white women did. African American women were 
less likely to give birth at late age (.36 years) compared 
with white women (26% versus 41%). Breast feeding 
seemed to only be associated with the mitotic index 
among white women where increasing lifetime duration 
of breastfeeding was associated with a non-statistically 
significant increase in mitotic index (Table 4).
Discussion
In this report, we demonstrated that, after adjusting 
for  known  breast  cancer  risk  factors,  high  mitotic 
index in cultured blood lymphocytes was significantly 
Table 2. Case-control comparison of mean mitotic index.
Host factors cases controls P-value
n Mean (sD) n Mean (sD)
All subjects 200 3.59 (1.2) 360 3.26 (1.0) ,0.01
Age
,55 124 3.65 (1.3) 196 3.31 (1.0) 0.05
>55 76 3.51 (1.0) 164 3.10 (1.0) 0.04
Race
White 147 3.59 (1.2) 224 3.35 (1.0) 0.03
African American 42 3.47 (1.2) 126 3.06 (1.0) 0.02
Active smoking
ever 71 3.59 (1.0) 148 3.21 (0.9) 0.01
never 126 3.61 (1.3) 208 3.30 (0.8) 0.02
Menopausal status
Pre- 85 3.53 (1.3) 138 3.28 (1.0) 0.08
Post- 108 3.69 (1.2) 218 3.26 (1.0) ,0.01
BMI categories
,20 14 4.09 (1.8) 19 3.64 (1.0) 0.37
20–25 65 3.75 (1.4) 135 3.52 (1.0) 0.13
26–30 54 3.49 (1.0) 88 3.07 (1.0) 0.01
.30 49 3.29 (1.0) 105 2.99 (0.9) 0.07
physical activity at age 13–19
Yes 130 3.53 (1.3) 277 3.28 (1.0) 0.03
no 68 3.70 (1.0) 74 3.22 (0.9) ,0.01
note: *P-values were computed using t-tests.
Abbreviation: BMi, body mass index.Blood lymphocyte proliferation index and breast cancer risk
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associated with an increased risk of breast cancer. This 
result seems support the concept that cellular hyper-
  proliferation in response to mitogens is associated with 
an increased risk of breast cancer. Although the endog-
enous factors that contribute to PHA-induced mitotic 
index phenotype are likely complex and remain to be 
elucidated by future studies, our data provided some 
clues that reproductive or other hormonal exposures 
may partly contribute to the mitotic index phenotype.
Our  data  is  not  in  agreement  with  a  previous 
report by Wiltschke et al showing that PHA-induced 
lymphocyte  proliferation  was  lower  in  breast  can-
cer patients compared with that in healthy women 
controls.20 There are several limitations in this pre-
vious small study (90 cases and 60 controls). First, 
recruitment of the study subjects was not described 
and it is unknown what type of control subjects were 
included in the analysis. Second, the characteristics 
of the study population were not described, thus it is 
hard to evaluate the comparability of the case-control 
population. Third, other known reproductive and host 
factors were not considered in the analysis. It is also 
Table 3. Logistic regression examining the association between mitotic index and breast cancer risk.
  cases/controls OR* (95% cI) cases/controls OR* (95% cI)
Mitotic index (%) All subjects
By median  
Low (#3.19) 74/178 1
high (.3.19) 126/182 1.54 (1.03–2.30)
By quartiles
Q1 (#2.59) 40/96 1
Q2 + Q3 (2.60–3.98) 83/173 1.20 (0.69–1.99)
Q4 ($3.99) 77/91 2.00 (1.16–3.47)
P trend ,0.01
White women African American women
By median
Low (#3.19) 56/104 1 16/71 1
high (.3.19) 91/120 1.46 (0.90–2.35) 26/55 1.44 (0.64–3.22)
By quartiles
Q1 (#2.59) 30/48 1 8/45 1
Q2 + Q3 (2.60–3.98) 60/115 0.93 (0.49–1.77) 20/56 1.77(0.65–4.80)
Q4 ($3.99) 57/61 1.76 (0.91–3.41) 14/25 2.10 (0.67–6.51)
P trend 0.04 0.19
premenopausal women postmenopausal women
By median  
Low (#3.19) 35/66 1 35/109 1
high (.3.19) 50/72 1.14 (0.62–2.09) 73/109 2.06 (1.18–3.57)
By quartiles
Q1 (#2.59) 19/36 1 18/58 1
Q2 + Q3 (2.60–3.98) 35/69 0.96 (0.44–2.09) 46/102 1.42 (0.69–2.81)
Q4 ($3.99) 31/33 1.68 (0.73–3.88) 44/58 2.41 (1.15–5.07)
P trend 0.17 ,0.01
BMI # 25 BMI . 25
By median  
Low (#3.19) 26/54 1 43/117 1
high (.3.19) 53/100 1.03 (0.51–2.05) 60/76 2.02 (1.19–3.43)
By quartiles
Q1 (#2.59) 18/29 1 20/64 1
Q2 + Q3 (2.60–3.98) 22/71 0.43 (0.16–1.16) 51/95 1.69 (0.88–3.25)
Q4 ($3.99) 39/54 1.50 (0.62–3.61) 32/34 2.49 (1.17–5.32)
P trend   0.07   0.02
notes: *ORs are adjusted for age, race, menopausal status (where appropriate), number of full term pregnancies and weeks of breastfeeding. Further 
adjustment for BMi resulted in comparable results.
Abbreviations: hRT, hormonal replacement therapy, analysis among post–menopausal women only; BMi, body mass index.Kosti et al
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Table 4. Correlation between mitotic index, host factors and reproductive factors in healthy controls (n = 360).
Host factors n (%) Mean (sD) n (%) Mean (sD) n (%) Mean (sD)
All (n = 360) White (n = 224) African American (n = 126)
Race 360 3.25 (1.0) 224 3.35 (1.0) 126 3.06 (0.9)
Age categories (y)
#45 78 (22) 3.39 (1.0) 45 3.40 (0.9) 31 (25) 3.22 (0.9)
46–55 118 (33) 3.26 (0.9) 71 3.39 (1.0) 42 (33) 3.00 (0.8)
56–65 102 (28) 3.30 (1.0) 63 3.46 (1.0) 36 (28) 3.08 (0.9)
$66 62 (17) 3.01 (1.0) 45 3.07 (0.9) 17 (14) 2.84 (1.1)
P trend   0.06   0.19   0.28
BMI
,20 19 (5) 3.63 (0.9) 16 (7) 3.78 (1.0) 2 (2) 2.34 (0.1)
20–25 135 (38) 3.49 (1.0) 107 (48) 3.53 (0.9) 23 (18) 3.27 (1.0)
26–30 88 (24) 3.10 (0.9) 48 (21) 3.11 (1.0) 36 (29) 3.09 (1.0)
.30 105 (29) 3.00 (0.9) 46 (21) 3.08 (1.0) 59 (47) 2.92 (0.8)
P trend   ,0.01   ,0.01   0.32
Reproductive factors
Age at menarche (y)
9–11 86 (24) 3.12 (1.0) 45 (20) 3.23 (1.0) 39 (31) 3.02 (1.0)
12 110 (30) 3.35 (0.9) 70 (31) 3.35 (1.0) 35 (28) 3.19 (1.0)
13 85 (24) 3.22 (1.0) 54 (24) 3.38 (0.9) 28 (22) 2.97 (1.0)
$14 76 (21) 3.34 (0.9) 53 (24) 3.47 (1.0) 23 (18) 3.05 (0.9)
P trend 0.04 ,0.01 0.65
FTp
never pregnant 69 (19) 3.29 (1.0) 47 (21) 3.30 (1.0) 19 (15) 3.23 (1.0)
no FTP 34 (9) 3.42 (0.9) 17 (8) 3.70 (0.9) 17 (13) 3.11 (0.8)
Yes FTP 254 (71) 3.23 (1.0) 158 (70) 3.34 (1.0) 89 (71) 3.01 (0.8)
P value 0.06 0.34 0.48
number of FTp
1 57 (22) 3.01 (1.0) 33 (21) 3.11 (1.0) 23 (26) 2.93 (0.9)
2 112 (44) 3.31 (0.9) 74 (47) 3.35 (1.0) 35 (39) 3.16 (0.9)
$3 85 (34) 3.26 (1.0) 51 (32) 3.45 (1.1) 31 (35) 2.89 (0.9)
P trend 0.13 ,0.01 0.94
Age of first FTP (y)
#20 30 (12) 2.92 (1.1) 3 (2) 2.84 (0.9) 25 (28) 2.85 (0.9)
21–24 59 (24) 2.99 (1.0) 31 (19) 3.14 (1.1) 27 (31) 2.77 (0.9)
25–29 64 (26) 3.50 (1.0) 44 (28) 3.63 (1.0) 17 (19) 3.21 (1.0)
$30 94 (38) 3.30 (1.0) 74 (47) 3.28 (1.0) 19 (21) 3.37 (1.0)
P trend 0.04 0.6 0.08
Age of last FTp
,30 78 (31) 3.14 (1.1) 33 (21) 3.44 (1.1) 41 (46) 2.73 (0.9)
30–35 83 (33) 3.27 (1.0) 56 (36) 3.38 (1.0) 25 (28) 3.18 (0.8)
36–40 67 (26) 3.35 (1.1) 48 (30) 3.38 (0.9) 18 (20) 3.28 (0.9)
$40 23 (9) 3.02 (1.0) 18 (11) 2.94 (1.3) 5 (6) 3.45 (1.3)
P trend 0.23 0.27 0.03
Years since last FTp
#10 51 (20) 3.29 (1.5) 36 (23) 3.10 (1.0) 14 (16) 3.35 (0.7)
11–20 56 (22) 3.24 (1.1) 36 (23) 3.23 (1.3) 18 (20) 3.26 (0.9)
21–30 68 (27) 3.29 (1.0) 36 (23) 3.53 (0.9) 32 (36) 3.00 (1.0)
$30 76 (30) 3.12 (1.6) 47 (29) 3.48 (1.0) 25 (28) 2.63 (0.9)
P trend 0.23 0.37 0.3
ever breastfed
Yes 178 (70) 3.28 (1.0) 130 (82) 3.40 (1.0) 44 (49) 3.13 (0.9)
no 76 (30) 3.13 (1.0) 28 (18) 3.32 (1.0) 45 (51) 2.94 (0.9)
P value 0.23 0.7 0.36
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Table 4. (Continued)
Host factors n (%) Mean (sD) n (%) Mean (sD) n (%) Mean (sD)
All (n = 360) White (n = 224) African American (n = 126)
Weeks breast feeding
#20 43 (24) 3.07 (1.0) 28 (22) 3.20 (1.0) 14 (32) 2.93 (0.9)
21–56 41 (23) 3.24 (1.0) 29 (22) 3.09 (1.0) 12 (27) 3.64 (0.8)
57–108 43 (24) 3.48 (1.0) 36 (28) 3.49 (1.1) 6 (14) 2.89 (1.2)
$109 47 (27) 3.39 (1.0) 35 (27) 3.48 (1.1) 10 (23) 2.92 (1.0)
P trend   0.11   0.12   0.91
notes: *P-trend and P-values were computed using general linear models adjusting for age and race apart from when age, race and menopausal status 
were examined. For analysis stratified by race, age adjusted values are presented. 
Abrrevaitons: FTP, full term pregnancy, analyses among parous women only, weeks breast feeding analysis was performed among women who breast 
fed; BMi, body mass index.
worth to note that the study by Wiltschke et al used 
purified  mononuclear  cells  by  Ficoll  gradient  cen-
trifugation for lymphocyte culture, while the present 
study used whole blood for lymphocyte cultures. It 
is possible that lymphocyte growth as measured by 
mitotic  index  in  our  culture  system  is  affected  by 
circulating hormonal and other factors in the blood 
serum.
We  found  that  mitotic  index  was  positively 
associated with number of full-term pregnancies and 
age at first full-term pregnancy, suggesting exposure 
to very high level of reproductive hormones   during 
pregnancy may increase PHA-induced mitotic index 
in  blood  lymphocytes.  The  ability  of  the    ovarian 
  hormones estrogen and progesterone to promote cell 
proliferation  in  the  normal  breast  epithelium  can 
explain  key  epidemiologic  observations  regarding 
reproductive history and breast cancer risk.25 However, 
whether the reproductive hormones influence the pro-
liferative potential of blood lymphocytes is unknown, 
although  estrogen  receptors  are  present  on  blood 
lymphocytes.26  Pregnancy  is  associated  with  very 
high levels of estrogen and progesterone that induce 
both cell proliferation and differentiation and there-
fore pregnancy is related to a dual effect on breast 
cancer; a short term increase in risk for up to 10 years 
after full term pregnancy and long term decrease.27 
The high levels of circulating reproductive hormones 
during pregnancy result in the differentiation of the 
terminal duct-lobular unit and confers a protective 
effect.28  Early  age  at  pregnancy,29  higher  parity30 
and prolonged lactation are found to be   protective 
against breast cancer.31 Additionally, it is well known 
that during pregnancy the maternal immune system 
and cytokine profile are modified in order to achieve 
immune tolerance towards paternal antigen expressed 
on  fetal  cells.32  It  is  therefore  possible  that  the 
observed associations between reproductive factors 
and the PHA-induced mitotic index in blood lympho-
cytes are the result of pregnancy-related endocrine 
and immune-function changes.
We  are  surprised  to  find  a  positive  correlation 
between  PHA-induced  mitotic  index  and  age  at 
menarche and an inverse correlation between PHA-
induced mitotic index and BMI. Both early age at 
menarche and obesity at post-menopausal result in 
prolonged exposure to physiological level estrogens 
and progesterone. Prolonged exposure to estrogens 
and progesterone are well documented risk factors 
for breast cancer. Early age at menarche (less than 
12 years of age) has been associated with a 10%–20% 
increase in breast cancer risk compared to late age 
(.14 years of age) at menarche.33 Obesity has a com-
plex relationship with breast cancer that was modu-
lated by menopausal status. In general, BMI has been 
found to be positively associated with breast cancer 
risk  among  postmenopausal  women,  whereas  it  is 
inversely associated with breast cancer risk among 
premenopausal women.34 Since adipose tissue is an 
important  source  of  estrogens35  in  postmenopausal 
women,  it  is  expected  that  obese  postmenopausal 
women have higher levels of endogenous estrogen 
than lean women. Our data seem to indicate that pro-
longed exposure to physiological levels of estrogens 
decreases PHA-induced mitotic index in blood lym-
phocytes, suggesting that the mitotic index phenotype 
might be a breast cancer risk factor independent of 
low level reproductive hormonal exposures.
We also found that the mitotic index was signifi-
cantly lower in African American women than in white Kosti et al
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women, which is consistent with African American 
women having lower overall breast cancer incidence 
compared with white women.3 Lower breast cancer 
incidence in African American women can be partially 
explained  by  the  differences  in  distributions  of  the 
two key reproductive risk factors, younger age at first 
full term pregnancy and parity.25 Approximately 50% 
of black women have their first child before age 20, 
whereas only 20% of white women have their first 
child at age ,20.36,37 Also, a higher proportion of white 
women have one or two children and black women 
more  often  have  three  or  more  children.37  African 
American  women  are  also  less  likely  to  breastfeed 
their children.38 In agreement with current literature we 
observed racial differences in reproductive factors and 
these could explain the differential effect of mitotic 
index as a marker of breast cancer risk. Given the fact 
that African American women tend to have their first 
and last child at an earlier age than white women and 
are less likely to breastfeed, the cumulative effect of 
reproductive  hormones  on  lymphocyte  proliferation 
during pregnancy would be shifted to an earlier age, 
thus may not be captured in our study population in 
which  greater  than  90%  of  the  women  were  older 
than 40 years of age. The small number of African 
American  cases  in  our  study  precluded  a  detailed 
analysis to understand racial differences in the asso-
ciation between mitotic index and breast cancer risk. 
Thus future larger studies are needed to characterize 
the relationship between PHA-induced mitotic index 
and breast cancer risk in African American women.
Given that this is a case-control study, a theoretical 
concern is that mitotic index in blood lymphocytes is 
affected by case status (reverse causality). To evaluate 
whether having breast cancer increases blood lympho-
cyte mitotic index, we examined if surgical removal 
of breast tumor affect the mitotic index among cases. 
We found that the mean mitotic index in blood samples 
collected before surgery (3.6%, n = 23) was similar to 
blood samples collected after surgery (3.6%, n = 89). 
We further examined the effect of time since surgery on 
the mitotic index in post-surgical cases. We observed 
that there were no significant changes in mitotic index 
between cases who’s blood was drawn within 30 days 
of post-surgery (3.5%, n = 32) and cases who’s blood 
was  drawn  between  30–60  days  of  post-surgery 
(3.8%,  n  =  34)  and  cases  who’s  blood  was  drawn 
between 60–180 days of post-surgery (3.2%, n = 23). 
There were no significant differences in mitotic index 
by stage of the disease (DCIS 3.9%, stage I–II 3.7% 
and stage III–IV 3.4%, P = 0.22) among cases. Our 
study is limited by its moderate sample size and do not 
have sufficient power for subgroup analyses. Thus, 
our results need to be replicated by large independent 
studies for more precise risk estimation. Other more 
relevant mitogens such as estrogens and interleukins 
should also be tested in future studies.
In  summary,  our  study  revealed  that  high  PHA-
  induced mitotic index in blood lymphocytes was signifi-
cantly associated with an increased risk of breast cancer. 
If confirmed by future studies, mitotic index of cultured 
blood lymphocytes may serve as an independent bio-
marker for breast cancer risk. Our data also suggested 
that this association may be modulated by menopausal 
status and BMI and its interactive effects with lifetime 
exposures to reproductive and other hormones on breast 
cancer risk warrants further investigation.
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